Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $2.2 million.

  • Alaunos Therapeutics' Shares Outstanding (Weighted Average) rose 3633.33% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 3633.33%. This contributed to the annual value of $1.6 million for FY2024, which is 10.75% up from last year.
  • As of Q3 2025, Alaunos Therapeutics' Shares Outstanding (Weighted Average) stood at $2.2 million, which was up 3633.33% from $1.7 million recorded in Q2 2025.
  • Alaunos Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $215.1 million for Q3 2022, and its period low was $1.6 million during Q2 2023.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $81.6 million, with a median of $2.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first tumbled by 9925.64% in 2023, then surged by 3633.33% in 2025.
  • Over the past 5 years, Alaunos Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $214.4 million in 2021, then crashed by 93.25% to $14.5 million in 2022, then crashed by 88.95% to $1.6 million in 2023, then increased by 0.11% to $1.6 million in 2024, then soared by 36.33% to $2.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $2.2 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.6 million for Q1 2025.